Open AccessChanges in Biomarkers of Inflammation and Angiogenesis During Androgen Deprivation Therapy for Prostate Cancer
Author(s) -
Saylor Philip J.,
Kozak Kevin R.,
Smith Matthew R.,
Ancukiewicz Marek A.,
Efstathiou Jason A.,
Zietman Anthony L.,
Jain Rakesh K.,
Duda Dan G.
Publication year - 2012
Publication title -
the oncologist
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.176
H-Index - 164
eISSN - 1549-490X
pISSN - 1083-7159
DOI - 10.1634/theoncologist.2011-0321
Subject(s) - medicine , prostate cancer , androgen deprivation therapy , angiogenesis , placental growth factor , basic fibroblast growth factor , inflammation , biomarker , cancer , stromal cell , tumor necrosis factor alpha , oncology , endocrinology , vascular endothelial growth factor , growth factor , receptor , biochemistry , chemistry , vegf receptors
. Angiogenesis and inflammation are both important to the pathogenesis of malignancies. Androgen deprivation therapy (ADT) for prostate cancer causes drastic hormonal changes that alter both disease and host factors. We measured inflammatory and angiogenic biomarkers in ADT‐treated and control groups of men with prostate cancer. Materials and Methods. Baseline and 12‐week plasma samples were collected from 37 ADT‐naïve men with locally advanced or recurrent prostate cancer. Of those, 23 initiated ADT with a gonadotropin‐releasing hormone (GnRH) agonist and 14 served as nontreatment controls. Samples were tested for a panel of angiogenic and inflammatory biomarkers. Results. The treatment group had significantly higher concentrations of the inflammatory biomarkers interleukin (IL)‐1β, IL‐6, IL‐8, tumor necrosis factor (TNF)‐α, and stromal cell–derived factor (SDF)‐1α. None of the angiogenic biomarkers were significantly different between the groups at baseline. Among patients with a short prostate‐specific antigen (PSA) doubling time (<6 months), the proangiogenic factor basic fibroblast growth factor (bFGF) was lower at baseline. In the treatment group, plasma placental growth factor (PlGF) increased and IL‐6 decreased after 12 weeks of ADT. Moreover, the treatment group continued to have significantly higher concentrations of the inflammatory biomarkers IL‐1β, IL‐8, and SDF‐1α as well as bFGF than controls. Discussion. These men were characterized by elevations in several traditional markers of aggressive disease and also by higher levels of several inflammatory biomarkers. Although ADT decreased IL‐6 levels, IL‐1β, IL‐8, and SDF‐1α remained significantly higher than in controls. The role of these biomarkers should be further explored.